BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004;110:260-5. [PMID: 15069691 DOI: 10.1002/ijc.20089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Walter B, Schrettenbrunner I, Vogelhuber M, Grassinger J, Bross K, Wilke J, Suedhoff T, Berand A, Wieland WF, Rogenhofer S, Andreesen R, Reichle A. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med Oncol 2012;29:799-805. [DOI: 10.1007/s12032-011-9982-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ito K, Yoshii H, Sato A, Kuroda K, Asakuma J, Horiguchi A, Sumitomo M, Asano T. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 2011;186:430-5. [PMID: 21679988 DOI: 10.1016/j.juro.2011.03.113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
3 Dutt V, Gupta S, Dabur R, Injeti E, Mittal A. Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action. Pharmacological Research 2015;99:86-100. [DOI: 10.1016/j.phrs.2015.05.010] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 12.9] [Reference Citation Analysis]
4 Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 2006;132:137-49. [PMID: 16308709 DOI: 10.1007/s00432-005-0058-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
5 Chitti SV, Marzan AL, Shahi S, Kang T, Fonseka P, Mathivanan S. Repurposing of Antibiotic Sulfisoxazole Inhibits Lipolysis in Pre-Clinical Model of Cancer-Associated Cachexia. Biology (Basel) 2021;10:700. [PMID: 34439933 DOI: 10.3390/biology10080700] [Reference Citation Analysis]
6 van Spronsen DJ, de Weijer KJM, Mulders PFA, De Mulder PHM. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs 2005;16:709-17. [DOI: 10.1097/01.cad.0000167901.58877.a3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
7 Harshman LC, Li M, Srinivas S. The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma—Is Not the Answer. American Journal of Clinical Oncology 2008;31:417-23. [DOI: 10.1097/coc.0b013e318168ef47] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, Schmidinger M. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691-698. [PMID: 16940978 DOI: 10.1038/sj.bjc.6603327] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
9 Weber K, Doucet M, Kominsky S. Renal cell carcinoma bone metastasis--elucidating the molecular targets. Cancer Metastasis Rev 2007;26:691-704. [PMID: 17768599 DOI: 10.1007/s10555-007-9090-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
10 Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 2008;71:79-86. [PMID: 18164847 DOI: 10.1016/j.ijrobp.2007.09.016] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
11 Zimmermann C, Gutmann H, Drewe J. Thalidomide does not interact with P-glycoprotein. Cancer Chemother Pharmacol 2006;57:599-606. [PMID: 16136308 DOI: 10.1007/s00280-005-0087-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
12 Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004;40:2377-82. [PMID: 15519508 DOI: 10.1016/j.ejca.2004.07.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
13 Murphy KT, Lynch GS. Update on emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs 2009;14:619-32. [DOI: 10.1517/14728210903369351] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
14 Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C. CT Quantification of Effects of Thalidomide in Patients with Metastatic Renal Cell Carcinoma. American Journal of Roentgenology 2007;189:378-85. [DOI: 10.2214/ajr.07.2164] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]